Skip to main content

Advertisement

Log in

Vasculitis induced by tumor necrosis factor-targeted therapies

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Tumor necrosis factor (TNF)-targeted therapies are increasingly used for a rapidly expanding number of rheumatic and autoimmune diseases. With this use and longer follow-up periods of treatment, there are a growing number of reports of the development of autoimmune processes related to these new therapeutic agents. We have analyzed the clinical characteristics, outcomes, and patterns of association with the different anti-TNF agents used in all reports of vasculitis developed after TNF-targeted therapy. A total of 132 cases, identified up to July 2008, are included and analyzed in this review.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Haraoui B: Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin Arthritis Rheum 2005, 34:7–11.

    Article  PubMed  CAS  Google Scholar 

  2. Nurmohamed MT, Dijkmans BA: Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs 2005, 65:661–694.

    Article  PubMed  CAS  Google Scholar 

  3. Bongartz T, Sutton AJ, Sweeting MJ, et al.: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275–2285.

    Article  PubMed  CAS  Google Scholar 

  4. Genovese MC, Bathon JM, Fleischmann RM, et al.: Long-term safety, efficacy and radiographic outcomes with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol 2005, 32:1232–1242.

    PubMed  CAS  Google Scholar 

  5. Lebwohl M, Gottlieb A, Wallis W, Zitnik R: Safety and efficacy of over 7 years of etanercept therapy in a global population of patients with rheumatoid arthritis. J Am Acad Dermatol 2005, 52:195.

    Google Scholar 

  6. Haraoui B, Keystone E: Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. Curr Opin Rheumatol 2006, 18:96–100.

    PubMed  Google Scholar 

  7. Rubin RL: Drug-induced lupus. Toxicology 2005, 209:135–147.

    Article  PubMed  CAS  Google Scholar 

  8. Anandacoomarasamy A, Kannangara S, Barnsley L: Cutaneous vasculitis associated with infliximab in the treatment of rheumatoid arthritis. Intern Med J 2005, 35:638–640.

    Article  PubMed  CAS  Google Scholar 

  9. Ashok D, Dubey S, Tomlinson I: C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab. Clin Rheumatol 2008, 27:261–264.

    Article  PubMed  Google Scholar 

  10. Brion PH, Mittal-Henkle A, Kalunian KC: Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med 1999, 131:634.

    PubMed  CAS  Google Scholar 

  11. Cocito D, Bergamasco B, Tavella A, et al.: Multifocal motor neuropathy during treatment with infliximab. J Peripher Nerv Syst 2005, 10:386–387.

    Article  PubMed  Google Scholar 

  12. Cunnane G, Warnock M, Fye KH, Daikh DI: Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis Rheum 2002, 47:445–449.

    Article  PubMed  Google Scholar 

  13. De Bandt M, Sibilia J, Le Loët X, et al.: Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005, 7:R545–R551.

    Article  PubMed  Google Scholar 

  14. Doulton TW, Tucker B, Reardon J, Velasco N: Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis. Clin Nephrol 2004, 62:234–238.

    PubMed  CAS  Google Scholar 

  15. Duffy TN, Genta M, Moll S, et al.: Henoch Schönlein purpura following etanercept treatment of rheumatoid arthritis. Clin Exp Rheumatol 2006, 24(2 Suppl 41):S106.

    PubMed  CAS  Google Scholar 

  16. Flendrie M, Vissers WH, Creemers MC, et al.: Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005, 7:R666–R676.

    Article  PubMed  CAS  Google Scholar 

  17. Galaria NA, Werth VP, Schumacher HR: Leukocytoclastic vasculitis due to etanercept. J Rheumatol 2000, 27:2041–2044.

    PubMed  CAS  Google Scholar 

  18. Goulão J, Cunha H, Anes I, et al.: Urticarial vasculitis due do infliximab. J Eur Acad Dermatol Venereol 2008, 22:882–883.

    Article  PubMed  Google Scholar 

  19. Jarand J, Zochodne DW, Martin LO, Voll C: Neurological complications of infliximab. J Rheumatol 2006, 33:1018–1020.

    PubMed  Google Scholar 

  20. Jarrett SJ, Cunnane G, Conaghan PG, et al.: Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 2003, 30:2287–2291.

    PubMed  Google Scholar 

  21. Juan A, Ribas B, Nadal C, Ros I: Treating leukocytoclastic vasculitis associated with etanercept therapy. Is it necessary to stop etanercept? J Rheumatol 2005, 32:2061.

    PubMed  Google Scholar 

  22. Lebas D, Staumont-Sallé D, Solau-Gervais E, et al.: Cutaneous manifestations during treatment with TNF-alpha blockers: 11 cases [French]. Ann Dermatol Venereol 2007, 134:337–342.

    Article  PubMed  CAS  Google Scholar 

  23. Lee A, Kasama R, Evangelisto A, et al.: Henoch-Schonlein purpura after etanercept therapy for psoriasis. J Clin Rheumatol 2006, 12:249–251.

    Article  PubMed  Google Scholar 

  24. Leydet-Quilici H, Luc M, Armingeat T, et al.: Giant cell arteritis during adalimumab treatment for rheumatoid arthritis. Joint Bone Spine 2007, 74:303–304.

    Article  PubMed  Google Scholar 

  25. Martinez-Taboada VM, Val-Bernal JF, Pesquera LC, et al.: Demyelinating disease and cutaneous lymphocitic vasculitis after etanercept therapy in a patient with rheumatoid arthritis. Scand J Rheumatol 2006, 35:322–323.

    Article  PubMed  CAS  Google Scholar 

  26. McCain ME, Quinet RJ, Davis WE: Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (Oxford) 2002, 41:116–117.

    Article  CAS  Google Scholar 

  27. McIlwain L, Carter JD, Bin-Sagheer S, et al.: Hypersensitivity vasculitis with leukocytoclastic vasculitis secondary to infliximab. J Clin Gastroenterol 2003, 36:411–413.

    Article  PubMed  CAS  Google Scholar 

  28. Mohan N, Edwards ET, Cupps TR, et al.: Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 2004, 31:1955–1958.

    PubMed  CAS  Google Scholar 

  29. Mor A, Bingham C 3rd, Barisoni L, et al.: Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol 2005, 32:740–743.

    PubMed  Google Scholar 

  30. Orpin SD, Majmudar VB, Soon C, et al.: Adalimumab causing vasculitis. Br J Dermatol 2006, 154:998–999.

    Article  PubMed  CAS  Google Scholar 

  31. Richette P, Dieude P, Damiano J, et al.: Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis. J Rheumatol 2004, 31:2079–2081.

    PubMed  Google Scholar 

  32. Richez C, Blanco P, Lagueny A, et al.: Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers. Neurology 2005, 64:1468–1470.

    PubMed  CAS  Google Scholar 

  33. Rodriguez-Escalera C, Belzunegui J, Lopez-Dominguez L, et al.: Multifocal motor neuropathy with conduction block in a patient with rheumatoid arthritis on infliximab therapy. Rheumatology (Oxford) 2005, 44:132–133.

    Article  CAS  Google Scholar 

  34. Roux CH, Brocq O, Albert C, et al.: Cutaneous vasculitis and glomerulonephritis in a patient taking the anti-TNF alpha agent etanercept for rheumatoid arthritis. Joint Bone Spine 2004, 71:444–445.

    Article  PubMed  Google Scholar 

  35. Saint Marcoux B, De Bandt M, CRI (Club Rhumatismes et Inflammation): Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine 2006, 73:710–713.

    Article  PubMed  CAS  Google Scholar 

  36. Seton M: Giant cell arteritis in a patient taking etanercept and methotrexate. J Rheumatol 2004, 31:1467.

    PubMed  Google Scholar 

  37. Simms R, Kipgen D, Dahill S, et al.: ANCA-associated renal vasculitis following anti-tumor necrosis factor alpha therapy. Am J Kidney Dis 2008, 51:e11–e14.

    Article  PubMed  Google Scholar 

  38. Singer OC, Otto B, Steinmetz H, Ziemann U: Acute neuropathy with multiple conduction blocks after TNFalpha monoclonal antibody therapy. Neurology 2004, 63:1754.

    PubMed  Google Scholar 

  39. Srivastava MD, Alexander F, Tuthill RJ: Immunology of cutaneous vasculitis associated with both etanercept and infliximab. Scand J Immunol 2005, 61:329–336.

    Article  PubMed  CAS  Google Scholar 

  40. Stokes MB, Foster K, Markowitz GS, et al.: Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005, 20:1400–1406.

    Article  PubMed  CAS  Google Scholar 

  41. Stübgen JP: Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 2008, 37:281–292.

    Article  PubMed  Google Scholar 

  42. Swale VJ, Perrett CM, Denton CP, et al.: Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol 2003, 28:604–607.

    Article  PubMed  CAS  Google Scholar 

  43. Tektonidou MG, Serelis J, Skopouli FN: Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment. Clin Rheumatol 2007, 26:258–260.

    Article  PubMed  Google Scholar 

  44. Wendling D, Streit G, Lehuede G, et al.: Cutaneous lymphocytic vasculitis during TNFalpha antagonist therapy for polyarthritis. Joint Bone Spine 2006, 73:215–216.

    Article  PubMed  Google Scholar 

  45. Maini RN, Breedveld FC, Kalden JR, et al.: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004, 50:1051–1065.

    Article  PubMed  CAS  Google Scholar 

  46. Kroesen S, Widmer AF, Tyndall A, Hasler P: Serious bacterial infections in patients with rheumatoid arthritis under anti- TNF-alpha therapy. Rheumatology 2003, 42:617–621.

    Article  PubMed  CAS  Google Scholar 

  47. Bieber J, Kavanaugh A: Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments. Rheum Dis Clin North Am 2004, 30:257–270.

    Article  PubMed  Google Scholar 

  48. Mohan N, Edwards ET, Cupps TR, et al.: Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001, 44:2862–2869.

    Article  PubMed  CAS  Google Scholar 

  49. Wolfe F, Michaud K: Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004, 50:1740–1751.

    Article  PubMed  CAS  Google Scholar 

  50. Ramos-Casals M, Brito-Zerón P, Muñoz S, et al.: Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine 2007, 86:242–251.

    Article  PubMed  Google Scholar 

  51. Merkel PA: Drug-induced vasculitis. Rheum Dis Clin North Am 2001, 27:849–862.

    Article  PubMed  CAS  Google Scholar 

  52. Gonzalez-Gay MA, Garcia-Porrua C, Pujol RM: Clinical approach to cutaneous vasculitis. Curr Opin Rheumatol 2005, 17:56–61.

    PubMed  Google Scholar 

  53. Ramos-Casals M, Nardi N, Lagrutta M, et al.: Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine 2006, 85:95–104.

    Article  PubMed  Google Scholar 

  54. Jennette JC, Falk RJ, Andrassy K, et al.: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994, 37:187–192.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Manuel Ramos-Casals.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ramos-Casals, M., Brito-Zerón, P., Cuadrado, MJ. et al. Vasculitis induced by tumor necrosis factor-targeted therapies. Curr Rheumatol Rep 10, 442–448 (2008). https://doi.org/10.1007/s11926-008-0072-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-008-0072-z

Keywords

Navigation